Will positive Phase III results for ITCA 650 versus Merck & Co.'s Januvia (sitagliptin) allow Intarcia Therapeutics to convince payers that its once- or twice-yearly diabetes medicine should be a first choice therapy for patients who fail to control their glucose with metformin?
ITCA 650 nearly doubled the glucose reduction and tripled the weight loss experienced by patients with type 2 diabetes compared...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
